Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

NOTICIAS


18 julio 2014

Enrolment complete in ROADSTER trial for carotid artery disease

Vascular News

Silk Road Medical has announced the completion of enrolment in its pivotal ROADSTER study. The trial was the first of its kind to study the treatment of carotid artery stenosis by placing a stent via direct access to the common carotid artery in the neck in an entirely new minimally invasive procedure. The device under study is the company’s Enroute transcarotid neuroprotection system which incorporates proven surgical principles to protect the brain from a stroke during carotid angioplasty and stenting, and features a mechanism to divert dangerous debris away from the brain by temporarily reversing blood flow. Data from the trial will be used to support 510(k) clearance of the Enroute transcarotid neuroprotection system as well as pre-market approval of the Enroute transcarotid stent system.

11 junio 2014

FDA Approves Covidien’s Apollo Onyx Delivery Microcatheter for Neurovascular Procedures

Endovascular Today

June 11, 2014—Covidien announced US Food and Drug Administration (FDA) approval of its Apollo Onyx delivery microcatheter. The detachable-tip microcatheter is designed to mitigate the technical challenges of catheter retrieval during Onyx liquid embolic system (LES) embolizations of brain arteriovenous malformations (bAVMs).

10 junio 2014

FDA Approves IDE for Pulsar Vascular’s PulseRider Aneurysm Neck Reconstruction Device

Endovascular Today

June 10, 2014—Pulsar Vascular announced that the US Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for the PulseRider, the company’s minimally invasive aneurysm neck reconstruction device. The IDE allows Pulsar Vascular to begin a multicenter clinical trial in support of a humanitarian device exemption to evaluate the PulseRider for United States approval for wide-neck aneurysms at or near a bifurcation of the basilar tip or carotid terminus.

10 junio 2014

FDA IDE approval for PulseRider

Interventional News

Pulsar Vascular has announced that the US Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for the PulseRider. The IDE allows Pulsar Vascular to begin a multicentre clinical trial in support of a humanitarian device exemption (HDE) to evaluate the PulseRider for US approval for wide neck aneurysms at or near a bifurcation of the basilar tip or carotid terminus. There are currently no devices approved by the FDA for this indication.

11 abril 2014

Covidien Recalls Pipeline and Alligator Devices

Endovascular Today

Covidien (Mansfield, MA) announced that it has notified customers of a voluntary recall to address an issue with certain lots of its Pipeline embolization device and Alligator retrieval device, in which the polytetrafluoroethylene (PTFE) coating applied to the delivery wire could delaminate and detach from the devices. Delamination of the PTFE coating could potentially lead to embolic occlusion in the cerebral vasculature, with the risk of stroke or death. The PTFE coating is used to reduce friction between devices and ease navigation through the vasculature.

12 mayo 2014

IsoRay´s Liquid Cesium-131 (Cesitrex(R)) Recieves Final Regulatory Approval for Use in GliaSite(R) Brain Cancer Treatment System

The Healthcare Sales & Marketing Network

RICHLAND, WA--(Healthcare Sales & Marketing Network) - IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced Isoray has received final approval from the State of Washington Department of Health to manufacture its recently FDA cleared Liquid Cesium-131 (Cesitrex®) for use with GliaSite® balloon catheter for the treatment of metastatic and glioblastoma brain cancers.

25 marzo 2014

Mazor Robotics Announces World´s First Renaissance(R) Asleep Deep Brain Stimulation Procedure

The Healthcare Sales & Marketing Network

-- (Healthcare Sales & Marketing Network) -- Mazor Robotics, Ltd. (TASE: MZOR; NASDAQ GM: MZOR), a developer of innovative guidance systems and complementary products, announced that for the first time ever, a surgeon utilized Mazor Robotics Renaissance Guidance System to perform an Asleep Deep Brain Stimulation (DBS) procedure earlier this month at Littleton Adventist Hospital in Littleton, Colo.

02 abril 2014

Mazor Robotics to Launch and Demo New Renaissance(R) Brain Module at American Association of Neurological Surgeons (AANS) Annual Meeting in San Francisco

The Healthcare Sales & Marketing Network

ORLANDO, Fla.--(Healthcare Sales & Marketing Network)--On April 7, 2014, Mazor Robotics (TASE:MZOR; NASDAQ GM:MZOR) will debut and officially launch the new Renaissance Guidance System brain module at the American Association of Neurological Surgeons (AANS) annual meeting. The Renaissance system is FDA-cleared for both spine and brain surgery.

04 abril 2014

Integra LifeSciences Announces Camino(R) Flex Ventricular Catheter Receives FDA Clearance for Use With MRI Scans

The Healthcare Sales & Marketing Network

PLAINSBORO, N.J., April 4, 2014 -- (Healthcare Sales & Marketing Network) -- Integra LifeSciences Holdings Corporation (IART) today announced that the Camino(R) Flex Ventricular Catheter has received clearance from the United States Food and Drug Administration (FDA) for use with magnetic resonance imaging (MRI). The Camino Flex Ventricular Catheter is an advanced, tunneled ventricular catheter that is MR conditional at 1.5 and 3.0 T, with a sensor designed to measure directly at the source, and is used with Integra´s next-generation Camino(R) Monitor, which debuted in 2013. Integra is a leading provider of advanced intracranial pressure monitoring (ICP) systems. Over 800 centers in the United States use the Camino platform for conditions that cause an elevated intracranial pressure, including traumatic brain injury, subarachnoid hemorrhage, and stroke.

10 abril 2014

Baxano Surgical Receives 510(k) Clearance for the Avance MIS Pedicle Screw System

The Healthcare Sales & Marketing Network

RALEIGH, N.C., April 10, 2014 -- (Healthcare Sales & Marketing Network) -- Baxano Surgical, Inc. (BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that it has received U.S. Food and Drug Administration 510(k) clearance (k133743) of its Avance(TM) MIS Pedicle Screw System, which may be used as an adjunct to fusion in numerous degenerative and complex spinal pathologies. The innovative design of Avance provides a quick and easy-to-use, percutaneous pedicle screw system that addresses single, complex and multi-level spinal pathologies with minimal tissue disruption and trauma. The Avance system will be in limited market release in the second and third quarter of 2014 and is planned for full launch in the fourth quarter of 2014.

14 abril 2014

Medicrea Announces European Launch of UNiD, the World´s First Patient-Specific Spinal Rod

The Healthcare Sales & Marketing Network

LYON, France--(Healthcare Sales & Marketing Network)--The MEDICREA group (ALMED.PA) (Alternext Paris: FR0004178572-ALMED), a company that specializes in the development of innovative surgical technologies for the treatment of spinal pathologies, today announced the European launch of the UNiD, the world´s first patient-specific spinal osteosynthesis rod system.

15 abril 2014

Reverse Medical(R) Corporation Announces FDA IDE Approval for the BARREL(R) Vascular Reconstruction Device for the Treatment of Intracranial Bifurcation Aneurysms

The Healthcare Sales & Marketing Network

IRVINE, Calif.--(Healthcare Sales & Marketing Network)--Reverse Medical® Corporation today announced FDA IDE approval for clinical investigation of their BARREL® Vascular Reconstruction Device (VRD). The BARREL® Vascular Reconstruction Device is designed for use with occlusive devices in the treatment of intracranial bifurcation aneurysms.

21 abril 2014

RTI Surgical(TM) Announces Launch of Streamline(R) OCT System

The Healthcare Sales & Marketing Network

ALACHUA, Fla.--(Healthcare Sales & Marketing Network)--RTI Surgical Inc. (RTI) (RTIX), a leading global surgical implant company, announced today the full market launch of the Streamline® OCT System. The system is designed to promote fusion of the occipto-cervico-thoracic spine (or occiput-T3). RTI received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the system in March 2014.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.